Filing Flows › Arbutus Biopharma (ABUS) › R&D spending
Arbutus Biopharma (ABUS) R&D spending by quarter
Arbutus Biopharma's R&D spending was $2.9M in Q2 2026 (second quarter 2026), -30% from Q1 2026. Over the last 6 quarters it ranged from $2.9M (Q2 2026) to $9.0M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $2.9M | -30% | -47% |
| Q1 2026 | $4.1M | -29% | -54% |
| Q3 2025 | $5.8M | +5% | — |
| Q2 2025 | $5.5M | -39% | — |
| Q1 2025 | $9.0M | +2% | — |
| Q4 2024 | $8.8M | — | — |
Q2 2026 at a glance
Arbutus Biopharma, Q2 2026: revenue $1.0M (-91% year over year), operating margin -588.2%, net loss $5.1M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Arbutus Biopharma's R&D spending?
Arbutus Biopharma's R&D spending was $2.9M in Q2 2026 (second quarter 2026), -30% from Q1 2026.
How has Arbutus Biopharma's R&D spending changed?
Over the last 6 quarters it ranged from $2.9M (Q2 2026) to $9.0M (Q1 2025).